News brief­ing: CG On­col­o­gy nets $47M Se­ries D for blad­der can­cer stud­ies; Sin­gle-cell tran­scrip­tom­ic start­up rais­es $24M launch cash

CG On­col­o­gy has some new cash to play with.

The Irvine, CA-based biotech an­nounced Thurs­day it closed a $47 mil­lion Se­ries D round of pre­ferred stock fi­nanc­ing as the com­pa­ny con­tin­ues to ad­vance late-stage tri­als for its lead pro­gram, CG0070. With the mon­ey, CG ex­pects to fund an on­go­ing Phase III study in non-mus­cle in­va­sive blad­der can­cer as a monother­a­py, as well as a com­bo Phase II tri­al with Mer­ck’s Keytru­da.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER